Skip to main content

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 2a Study to Evaluate the Mechanism of Action of Abrocitinib Monotherapy for Moderate-to-Severe Atopic Dermatitis (JADE MOA)